STOCK TITAN

Monthly information on share capital and company voting rights

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Cellectis announces voting rights for February 2024 with a total of 77,686,895 voting rights and 71,751,201 shares in the capital. The company's ISIN code is FR0010425595, listed on Euronext Growth.
Positive
  • None.
Negative
  • None.

PARIS, March 04, 2024 (GLOBE NEWSWIRE) --

(Article 223-16 of General Regulation of the French financial markets authority)

Listing market: Euronext Growth

ISIN code: FR0010425595

DateTotal number of shares
in the capital
Total number of voting rights
02/29/202471,751,20177,686,895

For further information on Cellectis, please contact:     

Media contact:       

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, media@cellectis.com  

Investor Relations contacts:       

Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com

Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577

Attachment


FAQ

What is the total number of voting rights for Cellectis in February 2024?

Cellectis had a total of 77,686,895 voting rights in February 2024.

How many shares are in the capital of Cellectis in February 2024?

Cellectis had 71,751,201 shares in the capital in February 2024.

Where is Cellectis listed?

Cellectis is listed on Euronext Growth.

What is the ISIN code for Cellectis?

Cellectis' ISIN code is FR0010425595.

Who can be contacted for media inquiries at Cellectis?

For media inquiries at Cellectis, contact Pascalyne Wilson at +33 (0)7 76 99 14 33 or Patricia Sosa Navarro at +33 (0)7 76 77 46 93.

Who are the Investor Relations contacts for Cellectis?

The Investor Relations contacts for Cellectis are Arthur Stril at +1 (347) 809 5980 and Ashley R. Robinson at +1 617 430 7577.

Cellectis S.A. American Depositary Shares

NASDAQ:CLLS

CLLS Rankings

CLLS Latest News

CLLS Stock Data

154.14M
93.36M
3.87%
16.65%
0.14%
Biotechnology
Healthcare
Link
United States of America
Paris